Madhya Pradesh Doctor Who Prescribed Deadly Cough Syrup To Children Arrested

The Madhya Pradesh government also filed a case against Srisan Pharmaceuticals, the company that manufactured the Coldrif syrup.

Bhopal: The doctor in Madhya Pradesh’s Chhindwara who prescribed Coldrif syrup to children has been arrested amid a massive row over the deaths of 11 children who allegedly took the contaminated cough syrups, officials said early Sunday. Most of the children were treated at the clinic of Praveen Soni, a paediatrician in Parasia.

Soni, a government doctor who prescribed the syrup to children during their visit to his private clinic, was also suspended.

The Madhya Pradesh government also filed a case against Srisan Pharmaceuticals, a company based in Tamil Nadu’s Kanchipuram district that manufactured the Coldrif cough syrup.

The government had earlier banned the sale of Coldrif, with officials saying that samples of the drug were found to contain 48.6 % diethylene glycol, a highly toxic substance. A sample of the syrup, tested by the government drug analyst at the Drug Testing Laboratory in Chennai, was declared “Not of Standard Quality” by the Tamil Nadu Directorate of Drug Control.

As a precautionary measure, the local administration banned the sale of Coldrif and another cough syrup, ‘Nextro-DS’, on Monday. The test report for Coldrif arrived on Saturday, while that of Nextro-DS is awaited.

According to distraught families, the children first complained of a cold and mild fever in early September. They were then prescribed routine medication, including cough syrups, after which they seemed to recover. But within days, the symptoms returned, followed by a sudden and alarming decrease in urine output. Their condition then worsened into kidney infections, and they later died.

Kidney biopsies then revealed the presence of diethylene glycol contamination.

Chief Minister Mohan Yadav called the deaths “extremely tragic” and said strict action will be taken against those responsible.

“The deaths of children in Chhindwara due to Coldrif syrup are extremely tragic. The sale of this syrup has been banned across Madhya Pradesh. A ban is also being imposed on the sale of other products from the company that manufactures the syrup,” he wrote on X on Saturday.

He said they asked the Tamil Nadu government to test Coldrif as the factory producing the syrup is located in Kanchipuram.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’